Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Look up keyword
Like this
1Activity
0 of .
Results for:
No results containing your search query
P. 1
Group III - Glucagon and Glucose Metabolism

Group III - Glucagon and Glucose Metabolism

Ratings: (0)|Views: 32|Likes:
Published by iqbal tambunan
Dari Prof. Dr. herbert Sipahutar M.Sc.,M.Si
sebagai tugas Fisiologi
Dari Prof. Dr. herbert Sipahutar M.Sc.,M.Si
sebagai tugas Fisiologi

More info:

Categories:Types, Research, Science
Published by: iqbal tambunan on Apr 04, 2012
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

01/22/2013

pdf

text

original

 
284:671-678, 2003. doi:10.1152/ajpendo.00492.2002
 Am J Physiol Endocrinol Metab
Guoqiang Jiang and Bei B. Zhang
You might find this additional information useful...
96 articles, 36 of which you can access free at:This article citeshttp://ajpendo.physiology.org/cgi/content/full/284/4/E671#BIBL27 other HighWire hosted articles, the first 5 are:This article has been cited by[PDF] [Full Text] [Abstract] , December 1,2008; 87(12): 2678-2688.
Poult. Sci.
J. Wang, Y. Wang, X. Li, J. Li and F. C. Leung
ReceptorCloning, Tissue Distribution, and Functional Characterization of Chicken Glucagon
[PDF] [Full Text] [Abstract] , February 17,2009; 2(58): pe8-pe8.
Sci. Signal.
A. Cheng and A. R. Saltiel
Von Gierke's Disease Adopts an Orphan (and Its Partner)
[PDF] [Full Text] [Abstract] , March 1,2009; 296(3): E415-E421.
 Am J Physiol Endocrinol Metab
S. Ali and D. J. Drucker
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes
[PDF] [Full Text] [Abstract] , April 1,2009; 329(1): 102-111.
and M. M. VeniantPatel, D. Caughey, G. S. Elliott, Y. Y. Lau, J. Wang, Y.-S. Li, T. Boone, R. A. Lindberg, S. HuH. Yan, W. Gu, J. Yang, V. Bi, Y. Shen, E. Lee, K. A. Winters, R. Komorowski, C. Zhang, J. J. 
Glucose Homeostasis in Mice and MonkeysFully Human Monoclonal Antibodies Antagonizing the Glucagon Receptor Improve
[PDF] [Full Text] [Abstract] , December 1,2009; 331(3): 871-881.
J. Yang, V. Bi, Y. Shen, S. Hu, T. Boone, R. A. Lindberg and M. M. VeniantW. Gu, H. Yan, K. A. Winters, R. Komorowski, S. Vonderfecht, L. Atangan, G. Sivits, D. Hill, 
Hyperplasia and HyperglucagonemiaCauses Sustained Improvement in Glycemic Control, with Reversible {alpha}-CellLong-Term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice
on the following topics:http://highwire.stanford.edu/lists/artbytopic.dtlcan be found at Medline items on this article's topics Medicine .. Management of DiabetesOncology .. GlucagonBiochemistry .. Glucose HomeostasisBiochemistry .. GlycogenolysisBiochemistry .. GluconeogenesisBiochemistry .. Carbohydrate Regulationincluding high-resolution figures, can be found at:Updated information and serviceshttp://ajpendo.physiology.org/cgi/content/full/284/4/E671can be found at:
 AJP - Endocrinology and Metabolism
aboutAdditional material and informationhttp://www.the-aps.org/publications/ajpendoThis information is current as of April 13, 2010 .
http://www.the-aps.org/.20814-3991. Copyright© 2005 by the American Physiological Society. ISSN: 0193-1849, ESSN: 1522-1555. Visit our website atorganization. It is published 12 times a year (monthly) by the American Physiological Society, 9650 Rockville Pike, Bethesda MDpublishes results of original studies about endocrine and metabolic systems on any level of 
 AJP - Endocrinology and Metabolism
  on pi  l   3  , 0  0  a j   p en d  o. p y  s i   ol   o g y . o g ownl   o a d  e d f   om 
 
-
Glucagon plays a key role in glucose metabolism in vivo. Administration of exogenous glucagon increasesglucose levels in fasted or fed animals (63, 96), andsimilar observations were made in humans (29, 42, 57).Consistent with its role as a counterregulatory hor-mone of insulin, glucagon raises plasma glucose levelsin response to insulin-induced hypoglycemia (29). Infact, glucagon administration is used clinically to treathypoglycemia in humans (14, 29, 35). Numerous ex vivo or in vitro studies have directly demonstrated thatglucagon stimulates glucose output from intact per-fused rat livers (7, 28, 43) resulting from increases inboth glycogenolysis and gluconeogenesis. Similarly,glucagon also stimulates glucose output from primaryhepatocytes in culture (60, 92, 93).Several lines of evidence indicate that glucagon is asensitive and timely regulator of glucose homeostasisin vivo. Small doses of glucagon are sufficient to inducesignificant glucose elevations (35, 57, 63). The effect of glucagon can occur within minutes and dissipate rap-idly (27). Glucagon is secreted from islets in a pulsatilefashion (65), and such pulsatile deliveries of glucagonare more effective in inducing hepatic glucose output in vitro, ex vivo, and in vivo (49, 66, 92).Conversely, there is ample evidence demonstratingthat inhibition of glucagon signaling in vivo leads to areduction in plasma glucose, or hypoglycemia. It wasshown that administration of polyclonal glucagon-neu-tralizing antibodies abolished the hyperglycemic re-sponse to exogenous glucagon in animals (83). A simi-lar observation was made using a high-affinitymonoclonal anti-glucagon antibody (11). Additionally,the monoclonal antibody reduced ambient blood glu-
  on pi  l   3  , 0  0  a j   p en d  o. p y  s i   ol   o g y . o g ownl   o a d  e d f   om 
 
/
/
/
/
/
/
/
s
q
s
q
2
  on pi  l   3  , 0  0  a j   p en d  o. p y  s i   ol   o g y . o g ownl   o a d  e d f   om 

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->